Stockscreener 앱 받기
315.80
2.92%
-9.50
시간 외 거래:
315.80
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision Medicines Inc (PRAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Praxis Precision Medicines Inc (PRAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Orbimed Advisors LLC Raises Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
SummitTX Capital L.P. Sells 4,791 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
TradingKey - TradingKey
PRAX|Praxis Precision Medicines Inc|Price:325.300|Chg%:+2.900 - TradingKey
Swiss National Bank Acquires 6,200 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Fifth Third Bancorp Acquires New Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Allspring Global Investments Holdings LLC Grows Stake in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
California Public Employees Retirement System Takes $13.58 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Affinity Asset Advisors LLC Has $54.77 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. Revenue Breakdown – NASDAQ:PRAX - TradingView
Praxis Precision Medicines Inc (PRAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Understanding the Setup: (PRAX) and Scalable Risk - Stock Traders Daily
ETFs Investing in Praxis Precision Medicines, Inc. Stocks - TradingView
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (PRAX) Bank of America Global Healthcare Conference 2026 summary - Quartr
PRAX stock trades around recent lows as Praxis Precision Medicines updates pipeline and cash runway - AD HOC NEWS
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Piper Sandler reiterates Praxis Precision Medicines stock rating By Investing.com - Investing.com Nigeria
PRAX Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
Piper Sandler reiterates Praxis Precision Medicines stock rating - Investing.com
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo
Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating - Investing.com
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Candriam S.C.A. Has $20.50 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $449 - Moomoo
Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says - Moomoo
Praxis Precision Medicines explores neurology pipeline as Nasdaq-listed biotech refines its focus - Ad Hoc News
Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com - Investing.com Nigeria
Praxis Precision Medicines Inc. (PRAX) Q1 2026 Earnings: Surprise Beat on EPS as Clinical Pipeline AdvancesRevenue Miss Report - dars.gov.et
Praxis (PRAX) CEO Marcio Souza gifts 23,121 shares, retains 56,495 - Stock Titan
Praxis Precision (PRAX) Partners with Remagine Labs for Innovati - GuruFocus
Praxis Precision Medicines Partners with Remagine Labs to Develop Innovative Transdermal Patch for Ulixacaltamide Delivery in Essential Tremor – Minichart - Minichart
Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor - Stock Titan
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - Investing News Network
Praxis bets on skin patch for essential tremor drug - Stock Titan
Praxis Precision Medicines and Remagine Labs Announce - GlobeNewswire
S&P 500 Futures Climb In Premarket Trading; Praxis Precision Meds, IREN Lead - Moomoo
S&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN Lead - Barron's
If You Invested $1,000 in Praxis Precision Medicines, Inc. (PRAX) - Stock Titan
PRAX stock. Praxis Precision Medicines holds the spotlight on thin news - Ad-hoc-news.de
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor - Stock Titan
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Enterprise value to revenue forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Jefferies Keeps Their Buy Rating on Praxis Precision Medicines (PRAX) - The Globe and Mail
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
We Think Praxis Precision Medicines (NASDAQ:PRAX) Can Easily Afford To Drive Business Growth - Moomoo
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Cuts Target Price to $719 - Moomoo
The Technical Signals Behind (PRAX) That Institutions Follow - Stock Traders Daily
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $510 to $1,200 - Moomoo
Enterprise value to EBIT forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Praxis sees encephalopathies asset relutrigine action date extended - MSN
1.97%
0.83%
자본화:
|
볼륨(24시간):